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Background: Mucus hypersecretion and excessive cytokine synthesis is associated with many of the pathologic
features of chronic airway diseases such as asthma. 6-Mercaptopurine (6-MP) is an immunosuppressive drug that is
widely used in several inflammatory disorders. Although 6-MP has been used to treat asthma, its function and
mechanism of action in airway epithelial cells is unknown.
Methods: Confluent NCI-H292 and MLE-12 epithelial cells were pretreated with 6-MP followed by stimulation
with TNFα or PMA. mRNA levels of cytokines and mucins were measured by RT-PCR. Western blot analysis was
performed to assess the phosphorylation of IκBα and luciferase assays were performed using an NFκB reporter
plasmid to determine NFκB activity. Periodic Acid Schiff staining was used to assess the production of mucus.
Results: 6-MP displayed no effect on cell viability up to a concentration of 15 μM. RT-PCR analysis showed that
6-MP significantly reduces TNFα- and PMA-induced expression of several proinflammatory cytokines in NCI-H292
and MLE-12 cells. Consistent with this, we demonstrated that 6-MP strongly inhibits TNFα-induced phosphorylation
of IκBα and thus attenuates NFκB luciferase reporter activity. In addition, 6-MP decreases Rac1 activity in MLE-12
cells. 6-MP down-regulates gene expression of the mucin Muc5ac, but not Muc2, through inhibition of activation of
the NFκB pathway. Furthermore, PMA- and TNFα-induced mucus production, as visualized by Periodic Acid Schiff
(PAS) staining, is decreased by 6-MP.
Conclusions: Our data demonstrate that 6-MP inhibits Muc5ac gene expression and mucus production in airway
epithelial cells through inhibition of the NFκB pathway, and 6-MP may represent a novel therapeutic target for
mucus hypersecretion in airway diseases.
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Chronic airway diseases such as asthma, chronic
bronchitis, cystic fibrosis, and chronic allergic rhinitis
are characterized by airway inflammation and mucus
hypersecretion. Airway mucus is a component of the
pulmonary innate immune function and plays a crucial
role in defense against infectious and environmental
agents [1–7]. Excessive mucus production is a hallmark
in the pathogenesis of several airway diseases as it in-
creases morbidity and mortality by obstructing mucocilary* Correspondence: c.j.devries@amc.uva.nl
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creativecommons.org/publicdomain/zero/1.0/clearance and air flow [8]. Goblet cells produce mucins, a
class of mucus glycoproteins that provide airway with
characteristic adhesiveness and viscoelasticity to maintain
epithelium homeostasis [3]. To date, more than 20 mucin
genes have been identified in airways. Among several
mucin genes, Muc5ac is a major constituent of the
mucous layer in the airways of humans with respiratory
diseases and therefore serves as a marker for mucus cell
hyperplasia [9, 10]. Numerous previous studies reported
that inflammatory cytokines, like TNFα, induce Muc5ac
gene expression through activation of the NFκB pathway
in lung epithelial cells [11]. NFκB is a major transcription
factor essential for regulation of both innate and adaptive
immunity, and inflammation. Inhibition of the NFκBarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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asthma both in experimental models and in humans
[12–14]. A putative NFκB site at −3594/−3581 was identi-
fied in the promoter region of Muc5ac which is respon-
sible for the increased Muc5ac expression following
stimulation with inflammatory cytokines in airway epithe-
lial cells [11].
Azathioprine is an immunosuppressive drug, which has
been used for more than five decades to treat many
inflammatory diseases [15–17]. Azathioprine is a pro-drug
that is rapidly converted to 6-mercaptopurine (6-MP). As
an immunosuppressive drug, 6-MP is widely used as a key
agent in organ transplant recipients to prevent allograft
rejection, as a maintenance drug for patients with infla-
mmatory bowel disease, to treat rheumatoid arthritis,
hematologic malignancies, chronic active hepatitis, and
lupus nephritis [17]. 6-MP has been shown to have anti-
inflammatory effects through inhibiting prostaglandin
synthesis and neutrophil trafficking into inflammatory
tissue [18] and Rac1 inhibition in T cells and gut epithelial
cells [19, 20]. Several randomized trials reported that
6-MP led to improvement in patient’s asthmatic symp-
toms, probably due to reducing airway inflammation [18].
It is also reported that 6-MP may be used as a steroid
sparing agent for patients with asthma [18]. Prolonged
treatment of 6-MP has also been shown to be effective in
the treatment of chronic asthma patients [17]. 6-MP may
reduce T-cell activation and regulate the T-helper (Th)1
response to maintain a balance between Th1 and Th2
response in asthma [21]. Despite its extensive use in many
clinical studies in asthma, the molecular mechanism
behind actions of 6-MP is poorly understood.
Given that 6-MP has both an anti-inflammatory func-
tion and an immune modulatory function, and also its as-
sociation with treatment of chronic asthma in humans, we
hypothesized that 6-MP may suppress mucus production
through inhibition of the NFκB pathway in airway epithe-
lial cells. Our results clearly demonstrate that 6-MP
strongly inhibits cytokine synthesis and mucus production
by reduced gene expression of Muc5ac through suppres-
sion of the NFκB pathway in airway epithelial cells.
Methods
Cell culture and transfection
Human mucoepidermoid carcinoma (NCI-H292) cells
were grown and maintained in RPMI 1640 medium (Life
Technologies) containing 10 % FCS and 1 % penicillin/
streptomycin. MLE-12 cells were grown in DMEM
medium (Life Technologies) containing 5 % FCS and 1 %
penicillin/streptomycin. For transient transfection experi-
ments, cells were seeded at density of 2.4 × 104 cells/ml
and were transfected with indicated plasmids using
Lipofectamine LTX plus transfection reagent (Life Tech-
nologies) according to manufacturer’s instructions.MTT assay
Cell viability was assessed by the MTT (3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide)
(Sigma) assay. Cells were seeded in a 96-well plate at a
density of 2.4 × 103 cells/well and incubated overnight.
Cells were made quiescent by incubation in medium with-
out FCS for 24 h and then treated with vehicle (DMSO)
or various concentrations of 6-MP (Sigma; 6-MP was dis-
solved in DMSO at a concentration of 10 mM) overnight
followed by FCS (10 % v/v) stimulation for 24 h. After the
incubation, cells were incubated with 10 μL of MTT re-
agent (5 mg/ml) for 3 h at 37 °C. The MTT reagent was
removed, 100 μL of isopropanol was added to each well
and incubated for 15 min. Colorimetric analysis was
performed with an ELISA plate reader. Each experiment
(in quadruplicate) was repeated at least three times.
Semi-quantitative RT-PCR
Semi-quantitative RT-PCR (RT-PCR) was performed as
described previously [22, 23]. Briefly, cells were serum-
starved for 24 h and were pre-treated overnight with
6-MP (10 μM) or BAY-117085 (NFkB inhibitor; 10 μM:
Calbiochem). After the incubation, cells were stimulated
with TNFα (R&D systems; 50 ng/ml) or PMA (Sigma;
1nM) for 6 h before harvesting. Acidic ribosomal
phosphoprotein P0 was used as a house-keeping gene.
The analysis of the data involved the so called LinReg
method described previously [24]. The following primers
were used for RT-PCR: RANTES forw: 5′-CGCTGTC
ATCCTCATTGC-3′, RANTES rev: 5′-CCACTGGTG-
TAGAAATACTCC-3′; IL-6 forw: 5′-CGCCTTCGGTCC
AGTTG-3′, IL-6 rev: 5′- TCGTTCTGAAGAGGTGAG
TG-3′; IL-12p35 forw: 5′- AGGAATGTTCCCATGCC
TTCAC-3′, IL-12 p35 rev: 5′- GCAACTCTCATTCT
TGGTTAATTC-3′; TNFα forw: 5′-AGGACACCATGA
GCACTGAAAG-3′, TNFα rev: 5′-AGGAGAGGCTGAG
GAACAAG-3′; IL-1β forw: 5′-TGGCAGAAAGGGAA
CAGAAAGG-3′, IL-1β rev: 5′- GTGAGTAGGAGAGG
TGAGAGAGG-3′; Muc5ac forw: 5′-GGAACTGTGG
GGACAGCTCTT-3′, Muc5ac rev: 5′-GTCACATTCCT
CAGCGAGGTC-3′; Muc2 forw: 5′-CAGCACCGATTG
CTGAGTTG-3′, Muc2 rev: 5′- GCTGGTCATCTCAAT
GGCAG-3′; P0 forw: 5′-TCGACAATGGCAGCATCTA
C-3′, P0 rev: 5′-ATCCGTCTCCACAGACAAGG-3′.
Western blot analysis
Western blot analysis was performed as described previ-
ously [22, 23]. Antibodies applied in western blot analysis
were phospho-specific (p)IkBα (Cell signaling; 1:500), and
β-actin (Cell signaling; 1:1000).
Periodic acid schiff staining
To evaluate the production of mucus glycoproteins,
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Fig. 1 Effect of 6-MP on airway epithelial cell viability. Serum-starved
NCI-H292 cells were pre-treated with 6-MP at the indicated
concentrations and MTT assays were performed to assess cell
proliferation. Values represent mean ± S.D. *, p≤ 0.05;
ns = non-significant
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TNFα (50 ng/ml) or PMA (1nM) for 24 h. After the
incubation, cells were fixed with formaldehyde for
30 min and mucus glycoconjugates were visualized by
PAS staining. Hematoxylin staining was also incorpo-
rated as a counterstain.
Luciferase assays
Cells were transiently transfected with a NFκB reporter
plasmid and a NFκB subunit p65 reporter plasmid using
Lipofectamine LTX plus transfection reagent according to
the manufacturer’s protocol and assay was described pre-
viously [25]. The construct containing the NFκB response
element of the minimal IL-6 promoter was kindly pro-
vided by Dr. Karolien De Bosscher (Ghent University,
Belgium) and was described previously [26]. The pRL-TK
Renilla reporter plasmid (Promega) was co-transfected as
an internal control for transfection efficiency. Luciferase
activity measurements were performed using the dual-
luciferase reporter assay system (Promega) and Glomax
multi detection system (Promega) according to the manu-
facturer’s protocol. Each experiment (in duplicate) was
repeated at least three times.
Immunofluorescence staining
Cells were seeded on cover slips and serum-starved for
24 h. After starvation, cells were treated with 6-MP over-
night and then stimulated with TNFα (50 ng/ml) for 24 h.
Cells were fixed with 4 % (w/v) Formal-Fix (Thermo
Scientific), washed and incubated with Muc5ac antibody
(Santa Cruz; 1:500). Following repeated washing steps
with PBS, protein localization was visualized by secondary
antibodies coupled to fluorescent dyes Alexa Fluor-568
or −488 (Molecular Probes). Nuclei were counterstained
with Hoechst (Molecular Probes).
Statistical analysis
All statistical analyses were carried out with GraphPad
Prism software (GraphPad Software, San Diego, Calif ).
Comparisons between two groups were done with the
Student t test for unpaired variables. Comparisons be-
tween more than two groups were analyzed by ANOVA.
Data are reported as mean ± SD. P values <0.05 were
considered as statistically significant.
Results
Effect of 6-MP on airway epithelial cell viability
6-MP is an immunosuppressive drug and is known to
associate with inhibition of proliferation of cells such as
T-lymphocytes, smooth muscle cells, endothelial cells
and intestinal epithelial cells, we sought to investigate
the effect of 6-MP on viability of airway epithelial cells
[19, 27–30]. To study this, a MTT assay was performed
using various concentrations of 6-MP in mucoepidermoidcarcinoma NCI-H292 cells. We found that 6-MP has no
effect on cell proliferation at concentrations up to 15 μM,
however it inhibits cell proliferation at a concentration of
20 μM (Fig. 1). No cell cytotoxicity was observed at
concentrations up to 15 μM (data not shown). Therefore,
we chose to study the effect of 6-MP at 10 μM in the
following experiments as it was also shown to be effective
in our previous studies with gut epithelial cells [19, 29].
Inhibition of the inflammatory response of airway
epithelial cells by 6-MP
We and others previously demonstrated that 6-MP
decreases the inflammatory response in various cells
such as endothelial cells, smooth muscle cells and gut
epithelial cells [19, 29, 30]. As inflammation is also a key
event in airway diseases, we investigated the effect of
6-MP on inflammation in NCI-H292 cells. 6-MP signifi-
cantly decreased TNFα-induced mRNA expression of
several proinflammatory cytokines such as RANTES,
IL-6, IL-12, and TNFα, but not IL-1β (Fig. 2). In
addition, 6-MP decreases PMA-induced mRNA expres-
sion of cytokines in NCI-H292 cells (Additional file 1:
Figure S1E-F). Similar data were obtained in mouse
alveolar epithelial MLE-12 cells (Additional file 1: Figure
S1A-B). Altogether, these data indicate that 6-MP has an
anti-inflammatory function in airway epithelial cells.
6-MP inhibits activation of the NFκB pathway
NFκB is a pleiotropic transcription factor that is acti-
vated in response to inflammatory cytokines, mitogens,
and infections in airway epithelial cells [11]. Having
established that 6-MP inhibits activation of the NFκB
pathway in endothelial cells [29], and based on its

































































































Fig. 2 6-MP decreases the inflammatory response in airway epithelial cells. Serum-starved NCI-H292 cells were pre-treated with 6-MP and then
stimulated with TNFα for 6 h. RT-PCR was performed to assess mRNA expression of RANTES (a), IL-6 (b), IL-12p35 (c), TNFα (d), and IL-1β (e).
Values represent mean ± S.D. *, p≤ 0.05. a.u = arbitrary units
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NFκB pathway in NCI-H292 cells. NCI-H292 cells were
serum-starved for 24 h and pretreated with 6-MP
followed by stimulation with TNFα for the indicated
time points. Western blot analysis shows that 6-MP
inhibits TNFα-induced phosphorylation of IκBα, an
inhibitory unit of NFκB (Fig. 3a). To corroborate these
findings, we performed a luciferase assay using an NFκB
luciferase reporter plasmid. Consistent with the above
findings, 6-MP significantly reduced TNFα-induced
NFκB activity in NCI-H292 cells (Fig. 3b). Previous stud-
ies showed that 6-MP exhibits an anti-inflammatory
function through inhibition of the NFκB subunit p65 in
a rat model of subarachnoid hemorrhage [31]. Therefore,
we investigated the effect of 6-MP on cells overexpress-
ing the NFκB subunit p65. We found that 6-MP attenu-
ates p65 activity indicating that 6-MP directly affects the
transcriptional activity of NFκB (Fig. 3c). In addition,
6-MP decreases PMA-induced NFκB activity in MLE-12
cells (Additional file 1: Figure S1C). In endothelial cells
and gut epithelial cells, 6-MP inhibits Rac1 activity[19, 29]. As a measure of Rac1 activity GTP-bound Rac1
was measured in MLE-12 cells and show to be reduced by
6-MP (Fig. 3d). Taken together, these data demonstrate
that 6-MP reduces the inflammatory response through
inhibition of the NFκB pathway at different levels.
6-MP attenuates Muc5ac mucin gene expression
Numerous studies reported that the NFκB pathway is in-
volved in regulation of Muc5ac gene expression in airway
epithelial cells [11]. Indeed, we also found that an NFκB
inhibitor markedly decreased mRNA expression of TNFα-
induced Muc5ac mucin gene expression in NCI-H292
cells, confirming the previously published results (Fig. 4a).
Since 6-MP reduces activation of the NFκB pathway,
we hypothesized that 6-MP may regulate Muc5ac gene
expression. To test our hypothesis, we performed RTPCR
analyses for Muc5ac gene expression following treatment
with 6-MP. As expected, we found that 6-MP significantly
decreased TNFα-and PMA-induced Muc5ac gene expres-
sion (Fig. 4b; Additional file 1: Figure S1D). In addition to































































































Fig. 3 6-MP inhibits activation of the NFκB pathway. a Serum-starved NCI-H292 cells were pre-treated with 6-MP and then stimulated with TNFα
for the indicated time periods. Western blot analysis for pIkBα was performed and β-actin was used as a loading control. b NCI-H292 cells were
transfected with a NFκB-reporter plasmid and TNFα-induced luciferase activity was measured in the absence and in the presence of 6-MP. c The
NFκB subunit p65 was overexpressed together with the NFκB-reporter plasmid and luciferase activity was measured after 36 h. The transfection
efficiencies were normalized using Renilla luciferase co-transfection. d Rac1 activity is decreased by 6-MP in MLE-12 cells. Values represent
mean ± S.D. *, p≤ 0.05. a.u = arbitrary units
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fibrosis [32, 33]. We therefore analyzed the mRNA expres-
sion of Muc2, but 6-MP has no effect on the mRNA
expression of Muc2, suggesting the selective regulation of
Muc5ac by 6-MP (Fig. 4c). We next investigated the effect
of 6-MP on Muc5ac protein expression using an immuno-
fluorescent assay. Consistent with mRNA data of Muc5ac,
6-MP strongly inhibits the TNFα-induced Muc5ac protein
expression (Fig. 4d). Altogether, we conclude from these
experiments that 6-MP-mediated inhibition of NFκB
reduces Muc5ac gene expression.
Mucus production is decreased by 6-MP
To further substantiate above findings, we performed
PAS staining to test whether 6-MP has any effect on
overall mucus production. Serum-starved NCI-H292
cells were pretreated with 6-MP followed by stimulationwith PMA or TNFα. Similar to TNFα, PMA has also
been shown to induce mucus production in airway
epithelial cells [34]. In line with reduced Muc5ac gene
expression, 6-MP markedly attenuated mucus produc-
tion in the untreated, PMA- and TNFα-stimulated NCI-
H292 cells (Fig. 5).
Discussion
Excessive mucus production is an important hallmark of
airway diseases such as asthma, cystic fibrosis, and chronic
obstructive pulmonary disease [8]. A promising approach
to attenuate airway inflammation is identification and
development of a useful drug that inhibits secretion and
production of mucins, the major constituents of airway
mucus. 6-MP is an immunosuppressive drug and was
reported to exhibit various biological effects such as









































































Fig. 4 6-MP decreases Muc5ac mucin gene expression. a Serum-starved NCI-H292 cells were treated with a NFκB inhibitor and then stimulated
with TNFα. RT-PCR was performed to assess mRNA expression of Muc5ac. b-c Serum-starved NCI-H292 cells were pre-treated with 6-MP and then
stimulated with TNFα, and RT-PCR was performed to assess mRNA expression of Muc5ac (b) and Muc2 (c). Values represent mean ± S.D. *, p≤ 0.05.
d Muc5ac protein expression was determined by immunofluorescence using the appropriate antibody, and Hoechst was used for nuclear staining.
a.u = arbitrary units
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asthmatic patients, its function as well as the mechan-
ism responsible for its action on airway epithelial cells
is unknown. In this study, we investigated the potential
effect of 6-MP on mucin gene expression and mucus
production in airway epithelial cells. For these studies,
we chose human NCI-H292 mucoepidermoid carcin-
oma and mouse lung epithelial MLE-12 cells, widely
used model systems to study mucin production, be-
cause various inflammatory stimuli induce mucin gene
transcription in these cells [35]. We demonstrated, to
the best of our knowledge for the first time, that 6-MP
significantly reduces both TNFα- and PMA-induced
Muc5ac mucin gene expression and mucus production
through inhibition of airway inflammation mediated by
NFκB pathway.As an immunosuppressive drug, 6-MP has been
shown inhibit proliferation of different cells such as
lymphocytes, smooth muscle cells, endothelial cells and
intestinal epithelial cells [19, 27–30]. Our present data
demonstrate that 6-MP has no effect on the prolifera-
tion of lung airway cells, however 6-MP exhibits cyto-
toxic effects at concentrations above 15 μM. Intestinal
epithelial cells are more sensitive to 6-MP, as a 10 μM
concentration was shown to inhibit the proliferation of
these cells [19], which may require further research.
Allergic asthma is well characterized by mucus hyper-
secretion and airway inflammation which eventually
leads to airway obstruction [5–7]. Airway epithelial
cells, in addition to other cells such as dendritic cells,
airway smooth muscle cells and lymphocytes, contri-





Fig. 5 6-MP inhibits mucus production in airway epithelial cells. Serum-starved NCI-H292 cells were treated with 6-MP and then stimulated with PMA
or TNFα. Mucus glycoconjugates were visualized by PAS staining. Hematoxylin staining was incorporated as a counterstain to visualize the nuclei
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crucial regulator of inflammation and immunity, and is
activated in bronchiolar epithelium both in humans
and mice [12–14]. Inhibition of NFκB activity has been
associated with a strong down-regulation of many of
the molecular events that culminate in airway inflam-
mation and structural damage of the lung in asthma.
6-MP has been demonstrated to be effective in the
treatment of inflammatory diseases such as inflamma-
tory bowel disease, rheumatoid arthritis and asthma,
probably through modulation of the NFκB pathway
[17, 29, 31]. Our present data further extend these find-
ings showing that 6-MP attenuates expression of several
proinflammatory cytokines, which are down-stream tar-
gets of NFκB, in airway epithelial cells. We demonstrate
that 6-MP decreases Rac1 activation, similarly as in other
cell types, however, in lung epithelial cells this did not
result in apoptosis as was observed in T cells [20]. Given
that Rac1 is an inducer of IκBα phosphorylation, 6-MP
inhibits this phosphorylation resulting in reduced NFκB
activity in airway epithelial cells. The mere fact that over-
expressed p65 as well as PMA-induced NFκB activity is
lowered may indicate that 6-MP also has a more direct in-
hibitory effect on NFκB, for which at present the exact
underlying mechanism is unknown.
Airway epithelial cells produce mucins, a class of
mucus glycoproteins, that are crucial in maintaining
epithelium homeostasis [3]. Under diseased conditions
such as asthma, exaggerated airway epithelial mucin
production leads to mucous plugging and ultimately to
death [8]. Although other mucins are present, Muc5ac
is a major constituent of airway mucus in humans [9, 10].
It is well documented that multiple inflammatory stimuli
such as TNFα induce the expression of Muc5ac throughactivation of NFκB in airway epithelial cells [11]. We have
shown here that 6-MP attenuates TNFα-induced Muc5ac
gene expression and mucus production in NCI-H292
cells. Even though Muc2, like Muc5ac, contains an NFκB
response element in its promoter [36], 6-MP failed to
suppress Muc2 gene transcription. Apparently, the
signaling pathways to induce Muc2 expression are
different from those of Muc5ac, also demonstrating the
selective regulation of 6-MP on Muc5ac. To gain
insight on the effect of 6-MP on overall mucus produc-
tion, PAS stainings were performed, revealing a dra-
matic decrease. 6-MP strongly inhibits both TNFα- and
PMA-induced mucus production probably through
inhibition of NFκB pathway. Although we did not
investigate the expression of all known mucins, one
may suggest that, in addition to Muc5ac, there are
more 6-MP sensitive mucin genes.Conclusions
In summary, we demonstrated that the immunosuppres-
sive drug 6-MP inhibits inflammatory response induced by
TNFα in human NCI-H292 and mouse MLE-12 lung cells.
In addition, 6-MP attenuates TNFα-induced Muc5ac ex-
pression and total mucus production through inhibition of
activation status of Rac1 and IκBα phosphorylation result-
ing in reduced NFκB activation in NCI-H292 cells. The
data presented in the current study disclosed a previously
unknown role of 6-MP in airway epithelial cells as an
efficacious mucoregulator. As these experiments were per-
formed in cultured cells, results may not be generalizable
to the airway epithelium in vivo and future studies should
focus on testing of 6-MP in animal models of allergic
airway inflammation.
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Additional file 1: Figure S1. 6-MP decreases PMA-induced
inflammatory response in airway epithelial cells. A-B; Serum-starved
MLE-12 cells were pre-treated with 6-MP and then stimulated with PMA
(1 nM) for 6 h. RT-PCR was performed to assess mRNA expression of
CXCL1 (A) and RANTES (B). C; MLE-12 cells were transfected with an
NFκB-reporter plasmid and PMA-induced luciferase activity was measured
in the in the presence of 6-MP. D-F; Serum-starved NCI-H292 cells were
pre-treated with 6-MP and then stimulated with PMA (1 nM) for 6 h.
RT-PCR was performed to assess mRNA expression of Muc5ac (D), IL-1β (E),
and RANTES (F). Values represent mean ± S.D; *, p≤ 0.05; a.u = arbitrary units.
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